| Market Cap | 11.48M | P/E | - | EPS this Y | 53.20% | Ern Qtrly Grth | - |
| Income | -2.16M | Forward P/E | -0.84 | EPS next Y | 24.30% | 50D Avg Chg | -6.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -10.00% |
| Dividend | N/A | Price/Book | 1.27 | EPS next 5Y | - | 52W High Chg | -67.00% |
| Recommedations | 1.50 | Quick Ratio | 11.90 | Shares Outstanding | 2.90M | 52W Low Chg | 56.00% |
| Insider Own | 4.08% | ROA | -34.72% | Shares Float | 2.63M | Beta | -0.15 |
| Inst Own | 8.59% | ROE | -37.08% | Shares Shorted/Prior | 8.47K/10.52K | Price | 0.64 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 44,048 | Target Price | 12.25 |
| Oper. Margin | - | Earnings Date | May 15 | Volume | 7,556 | Change | 0.54% |
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. The company has a collaboration and license agreements with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in patients hospitalized with COVID-19; and with the University of Florida Research Foundation, Inc. XORTX Therapeutics Inc. is based in Alberta Beach, Canada.
